Today we announced that BlueBee has been awarded the Frost & Sullivan 2017 European Enabling Technology Leadership Award.
Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that enhances current products and enables the development of new products and applications that address global challenges. We are honored to be recognised by Frost & Sullivan with this year’s Award for best practices in Enabling Technology Leadership in the Cloud Based Genomic Solution industry. This notable award reiterates our market acceptance and the potential of BlueBee’s technology to achieve a difference in the global challenging sequence data analysis space. BlueBee was chosen after industry analysts compared market participants and measured performance based on in-depth interviews, analysis, and extensive secondary research, to identify best practices in the industry.
The BlueBee Genomics Platform is designed to tackle one of the most computationally challenging domains in the life sciences industry: Accelerated and cost-controlled analysis of the rapidly increasing number of genomes, within a secure and compliant environment.
Hans Cobben, BlueBee’s CEO, will receive the prestigious Frost & Sullivan 2017 European Enabling Technology Leadership Award at the Excellence in Best Practice Awards Banquet in London on 28th June.
Below are some highlights of the report or you access the full report.
Commitment to Innovation
Unlike other genome analysis providers claiming faster analysis, BlueBee does not cut short the algorithms. BlueBee speeds up gold standard algorithms, such as GATK or BWA, providing high-sensitivity and -specificity analytics. According to the German Cancer Research Center (DKFZ), the BlueBee platform accelerates BWA-ALN by 10 to 20 times and BWA-MEM by 3 to 4 times, thereby reducing the bioinformatics workflow by 50%. According to a case study in Center for Personalized Cancer Treatment, Netherlands, genome data analysis that once took 5 days can be performed in just 2 days with the BlueBee platform providing faster diagnosis and a predictable turnaround time regardless of the number of patients.
Commitment to Creativity
Several laws and regulations prevent uncontrolled sharing of sensitive data. BlueBee’s regulatory-compliant platform allows users to securely store, share, and use sequencing data in a choice or combination of 29 compliant data centers in major European countries and the United States. This feature helps in controlling the data residency, which makes the sensitive genomics data not leave the country data center into some public cloud, maintaining data privacy regulations. BlueBee and its data centers comply with standards including ISO 27001, the US Health Insurance Portability and Accountability Act of 1996 (HIPAA) and EU Model Clauses for regional data storage and processing. The platform segregates and encrypts customer data both in flight and at rest. Immutability and authenticity is maintained by digital signing of genomic data files. The owner keeps full control of the data; BlueBee never shares use or accesses the data for analysis by a third party.
Stage Gate Efficiency
BlueBee’s high-performance cloud solution enables flexible genomic pipeline configuration and easy migration. It supports labs by providing fast, efficient and affordable next-generation sequencing (NGS) analysis, and accelerates their go-to-market process. BlueBee has preconfigured, validated, off-the-shelf pipelines that can be used directly on its cloud platform, but also gives users the flexibility to configure their own pipeline. BlueBee also provides lift-over service to assist in the migration of an in-house pipeline onto the BlueBee platform.
The platform’s interactive data exploration and visualization is another unique feature. The use of Broad Institute’s Integrative Genomics Viewer enables a smooth viewing interface of large heterogeneous data sets, such as array-based and NGS data, and genomic annotations, at all levels of genome resolution.
BlueBee’s platform offers unlimited scaling up of computing and storage capacity, without the need for upfront investment or capital expenditure by maintaining an in-house computer cluster. BlueBee’s fee-per-sample business model is all-inclusive, with no set-up, subscription, maintenance, or licensing costs. Billing is either pay-as-you-go or based on volume. Migration to BlueBee private cloud is easy and affordable. Frost & Sullivan believes BlueBee’s team of experts provides rapid on-boarding services and hand-held migration of in-house genomic pipelines to help researchers who are at the research and clinical crossroads. DKFZ is using the BlueBee solution for the entire outcome of its sequencers.
Again, we are very honored for being recognized for achievements.